{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:56:03Z","timestamp":1763747763866},"reference-count":21,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2018.04.003","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T22:43:18Z","timestamp":1523313798000},"page":"4701-4709","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of combined drugs therapy on the course of clinical rabies infection in a murine model"],"prefix":"10.1016","volume":"37","author":[{"given":"Marcin","family":"Smreczak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Or\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Marzec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Tr\u0119bas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kycko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope","family":"Koraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert D.M.E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Franciszek","family":"\u017bmudzi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.04.003_b0005","first-page":"959","volume":"363","author":"Warrell","year":"2004","journal-title":"Rabies Other Lyssavirus Diseases"},{"key":"10.1016\/j.vaccine.2018.04.003_b0010","first-page":"9","volume":"36","author":"Jackson","year":"2017","journal-title":"Manag Rabies Humans"},{"key":"10.1016\/j.vaccine.2018.04.003_b0015","first-page":"66","article-title":"A case of human survival of rabies, South Africa","volume":"31","author":"Weyer","year":"2016","journal-title":"South Afr J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.003_b0020","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1056\/NEJMoa050382","article-title":"Survival after treatment of rabies with induction of coma","volume":"352","author":"Willoughby","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.04.003_b0025","first-page":"1","article-title":"Ribavirin has an in vitro antiviral effect in rabies virus infected neuronal cells but fails to provide benefit in experimental rabies in mice","volume":"2","author":"Appolinario","year":"2013","journal-title":"J Virol Antivir Res"},{"key":"10.1016\/j.vaccine.2018.04.003_b0030","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/bmj.299.6703.830","article-title":"Failure of interferon alfa and tribavirin in rabies encephalitis","volume":"299","author":"Warrell","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.04.003_b0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ana.410160116","article-title":"Human leukocyte interferon administration to patients with symptomatic and suspected rabies","volume":"16","author":"Merigan","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2018.04.003_b0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13337-015-0269-5","article-title":"Exogenous interferon prolongs survival of rabies infected mice","volume":"26","author":"Mehta","year":"2015","journal-title":"VirusDisease"},{"key":"10.1016\/j.vaccine.2018.04.003_b0045","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of lassa fever","volume":"213","author":"Oestereich","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.003_b0050","doi-asserted-by":"crossref","unstructured":"Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), A broad spectrum inhibitor of viralRNApolymerase 2017; 93: 449\u201363.","DOI":"10.2183\/pjab.93.027"},{"key":"10.1016\/j.vaccine.2018.04.003_b0055","doi-asserted-by":"crossref","unstructured":"Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. Ef fi cacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis 2016; 213: 1253\u201361. doi: 10.1093\/infdis\/jiv586.","DOI":"10.1093\/infdis\/jiv586"},{"issue":"33","key":"10.1016\/j.vaccine.2018.04.003_b0060","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1016\/j.vaccine.2017.10.109","article-title":"Re-evaluating the effect of Favipiravir treatment on rabies virus infection","volume":"37","author":"Banyard","year":"2019","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2018.04.003_b0065","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1016\/j.vaccine.2017.10.098","article-title":"The effect of selected molecules influencing the detrimental host immune response on a course of rabies virus infection in a murine model","volume":"37","author":"Smreczak","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.003_b0070","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.micpath.2017.09.044","article-title":"Inhibition of MEK-ERK1\/2-MAP kinase signalling pathway reduces rabies virus induced pathologies in mouse model","volume":"112","author":"Manjunatha","year":"2017","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2018.04.003_b0075","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/IJN.S61288","article-title":"Current approaches to enhance CNS delivery of drugs across the brain barriers","volume":"9","author":"Lu","year":"2014","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.vaccine.2018.04.003_b0080","unstructured":"OIE. Rabies (infection with RABV). Man. Diagnostic Tests Vaccines Terrestial Anim., 2013, p. 2.1.17:1-28."},{"key":"10.1016\/j.vaccine.2018.04.003_b0085","first-page":"71","article-title":"An improvement of the 2\u0302(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis","volume":"3","author":"Rao","year":"2013","journal-title":"Biostat Bioinforma Biomath"},{"key":"10.1016\/j.vaccine.2018.04.003_b0090","doi-asserted-by":"crossref","unstructured":"Koraka P, Martina BEE, Roose JM, van Thiel PPAM, van Amerongen G, Kuiken T, et al. In vitro and in vivo isolation and characterization of Duvenhage virus. PLoS Pathog 2012; 8. doi: 10.1371\/journal.ppat.1002682.","DOI":"10.1371\/journal.ppat.1002682"},{"key":"10.1016\/j.vaccine.2018.04.003_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.79.18.11801-11812.2005","article-title":"Rabies virus-induced activation of mitogen-activated protein kinase and NF-kappaB signaling pathways regulates expression of CXC and CC chemokine ligands in microglia","author":"Nakamichi","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.04.003_b0100","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000357309","article-title":"Evaluation of neuroimmunomodulatory activity of recombinant human interferon?","volume":"21","author":"Mehta","year":"2014","journal-title":"Neuroimmunomodulation"},{"issue":"33","key":"10.1016\/j.vaccine.2018.04.003_b0105","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1016\/j.vaccine.2018.04.002","article-title":"Inhibition of caspase-1 prolongs survival of mice infected with rabies virus","volume":"37","author":"Koraka","year":"2019","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18304717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18304717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T21:44:05Z","timestamp":1564177445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18304717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":21,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X18304717"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of combined drugs therapy on the course of clinical rabies infection in a murine model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}